|
End-of-day quote
Korea S.E.
08/05/2026
|
5-day change
|
1st Jan Change
|
|
198,400.00 KRW
|
-2.02%
|
 |
-1.05%
|
+9.61%
|
|
05-08 |
Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on April 22, 2026.
|
CI
| |
05-06 |
Celltrion's Net Attributable Income Jumps 219% in Q1
|
MT
| |
05-06 |
Celltrion to Retire KRW100 Billion Worth of Treasury Shares
|
MT
| |
05-06 |
Celltrion Q1 operating profit 322 billion won, up 115% Y/Y
|
RE
| |
05-06 |
Celltrion to cancel 100 billion won treasury shares
|
RE
| |
05-05 |
Celltrion, Inc.'s Equity Buyback announced on April 22, 2026, has expired with 488,977 shares, representing 0.22% for KRW 99,999.87 million.
|
CI
| |
04-29 |
Celltrion, Inc. agreed to acquire Gifrer Barbezat SAS.
|
CI
| |
04-24 |
Celltrion plans phase 3 clinical trials for Keytruda biosimilar with 220 patients
|
RE
| |
04-22 |
Celltrion, Inc. authorizes a Buyback Plan.
|
CI
| |
04-22 |
Celltrion, Inc. announces an Equity Buyback for 492,611 shares.
|
CI
| |
04-22 |
Celltrion to buy 100 billion won of own shares
|
RE
| |
04-08 |
Nomura Adjusts Celltrion's Price Target to KRW270,000 From KRW240,000, Keeps at Buy
|
MT
| |
03-24 |
Celltrion : Announces KRW 1.2Tn Expansion of New DS Production Facilities in Songdo; Adds 180,000L of DS capacity, bringing total capacity to 570,000L
|
PU
| |
03-24 |
Celltrion to Build Two New Plants in Songdo Campus
|
MT
| |
03-23 |
Worker Dies After Fatal Fall at Celltrion's Incheon Plant; Shares Decline 6%
|
MT
| |
03-17 |
Celltrion Launches Anti-Inflammatory Drug Biosimilar in US; Shares Rise 3%
|
MT
| |
03-17 |
Celltrion : signs supply agreement with a global biopharma worth up to KRW 375.4 billion, reflecting recognition of product quality and manufacturing productivity, and accelerating CDMO growth
|
PU
| |
03-17 |
Celltrion Secures Pharmaceutical Manufacturing Contract; Shares Rise 3%
|
MT
| |
03-16 |
Celltrion Inc Announces U S Availability Of AVTOZMA® (tocilizumab-anoh) Subcutaneous (SC) Formulation
|
CI
| |
03-16 |
Celltrion announces U.S. availability of Avtozma® (tocilizumab-anoh) subcutaneous (SC) formulation
|
RE
| |
03-16 |
Celltrion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
|
CI
| |
03-11 |
Celltrion : launches Remsima IV liquid formulation in Europe, securing new competitiveness to lead the global infliximab market
|
PU
| |
03-11 |
Celltrion Launches Chronic Autoimmune Disease Drug in Europe; Shares Rise 3%
|
MT
| |
03-09 |
Celltrion Expands Treasury Share Cancellation
|
MT
| |
03-06 |
Celltrion to expand treasury share cancellation to 9.11 million shares: Prioritizing shareholder value amid heightened market uncertainty
|
PU
|
No results for this search Select your edition All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
| 
